Biosimilar Monoclonal Antibodies Market Worth Around 15200 Million USD by 2025: Exponential CAGR 27.7% in Global Market

London, UK -- (SBWire) -- 04/12/2019 --The "Global Biosimilar Monoclonal Antibodies Market" is an in depth study analyzing the current state and forecast 2018-2025. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Global Biosimilar Monoclonal Antibodies Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape. Competitive analysis includes competitive information of leading players in market, their company profiles, product portfolio, capacity, production, and company financials. In addition, report also provides upstream raw material analysis and downstream demand analysis along with the key development trends and sales channel analysis. Research study on Global Biosimilar Monoclonal Antibodies Market discusses the opportunity areas for investors.

The report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Download Sample Copy Of This Report From Here:http://www.amecoresearch.com/sample/11735

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%.
Biosimilar Monoclonal Antibodies is widely used for Oncology, Autoimmune Disease and Others. The most proportion of Biosimilar Monoclonal Antibodies is sales in Autoimmune Disease, and the consumption proportion is about 85.6% in 2017.

Global Biosimilar Monoclonal Antibodies market is valued at 2750 million US$ in 2018 and will reach 15200 million US$ by the end of 2025, growing at an exponential CAGR of 27.7% during 2019-2025.

The objectives of this study are to define, segment, and project the size of the Biosimilar Monoclonal Antibodies market based on company, product type, end user and key regions.

View Detail Report With Complete Table of Content@ http://www.amecoresearch.com/market-report/global-biosimilar-monoclonal-antibodies-market-arr-11735

This report studies the global market size of Biosimilar Monoclonal Antibodies in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Biosimilar Monoclonal Antibodies in these regions.

This research report categorizes the global Biosimilar Monoclonal Antibodies market by top players/brands, region, type and end user. This report also studies the global Biosimilar Monoclonal Antibodies market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy's
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals

Market size by Product
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Market size by End User
Oncology
Autoimmune Disease
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

Available customization:

With the given market information, Ameco research offers customization's in line with the company's specific wishes. The following customization choices unit of measurement accessible for the report:
Regional and country-level analysis of the Global Biosimilar Monoclonal Antibodies Market, by end-use.
Detailed analysis and profiles of additional market players.

Table of Contents

Global Biosimilar Monoclonal Antibodies Market Insights, Size, Share, Trend and Forecast 2018-2025

1 Study Coverage
1.1 Biosimilar Monoclonal Antibodies Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Product
1.4.2 Infliximab
1.4.3 Rituximab
1.4.4 Trastuzumab
1.4.5 Adalimumab
1.4.6 Other
1.5 Market by End User
1.5.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by End User
1.5.2 Oncology
1.5.3 Autoimmune Disease
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Biosimilar Monoclonal Antibodies Market Size
2.1.1 Global Biosimilar Monoclonal Antibodies Revenue 2014-2025
2.1.2 Global Biosimilar Monoclonal Antibodies Sales 2014-2025
2.2 Biosimilar Monoclonal Antibodies Growth Rate by Regions
2.2.1 Global Biosimilar Monoclonal Antibodies Sales by Regions
2.2.2 Global Biosimilar Monoclonal Antibodies Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Biosimilar Monoclonal Antibodies Sales by Manufacturers
3.1.1 Biosimilar Monoclonal Antibodies Sales by Manufacturers
3.1.2 Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers
3.1.3 Global Biosimilar Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
3.2 Biosimilar Monoclonal Antibodies Revenue by Manufacturers
3.2.1 Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2014-2019)
3.2.2 Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers (2014-2019)
3.3 Biosimilar Monoclonal Antibodies Price by Manufacturers
3.4 Biosimilar Monoclonal Antibodies Manufacturing Base Distribution, Product Types
3.4.1 Biosimilar Monoclonal Antibodies Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Biosimilar Monoclonal Antibodies Product Type
3.4.3 Date of International Manufacturers Enter into Biosimilar Monoclonal Antibodies Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Biosimilar Monoclonal Antibodies Sales by Product
4.2 Global Biosimilar Monoclonal Antibodies Revenue by Product
4.3 Biosimilar Monoclonal Antibodies Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Biosimilar Monoclonal Antibodies Breakdown Data by End User

6 North America
6.1 North America Biosimilar Monoclonal Antibodies by Countries
6.1.1 North America Biosimilar Monoclonal Antibodies Sales by Countries
6.1.2 North America Biosimilar Monoclonal Antibodies Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Biosimilar Monoclonal Antibodies by Product
6.3 North America Biosimilar Monoclonal Antibodies by End User

7 Europe
7.1 Europe Biosimilar Monoclonal Antibodies by Countries
7.1.1 Europe Biosimilar Monoclonal Antibodies Sales by Countries
7.1.2 Europe Biosimilar Monoclonal Antibodies Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Biosimilar Monoclonal Antibodies by Product
7.3 Europe Biosimilar Monoclonal Antibodies by End User

8 Asia Pacific
8.1 Asia Pacific Biosimilar Monoclonal Antibodies by Countries
8.1.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Countries
8.1.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Biosimilar Monoclonal Antibodies by Product
8.3 Asia Pacific Biosimilar Monoclonal Antibodies by End User

9 Central & South America
9.1 Central & South America Biosimilar Monoclonal Antibodies by Countries
9.1.1 Central & South America Biosimilar Monoclonal Antibodies Sales by Countries
9.1.2 Central & South America Biosimilar Monoclonal Antibodies Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Biosimilar Monoclonal Antibodies by Product
9.3 Central & South America Biosimilar Monoclonal Antibodies by End User

10 Middle East and Africa
10.1 Middle East and Africa Biosimilar Monoclonal Antibodies by Countries
10.1.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Countries
10.1.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Biosimilar Monoclonal Antibodies by Product
10.3 Middle East and Africa Biosimilar Monoclonal Antibodies by End User

11 Company Profiles
11.1 Celltrion
11.1.1 Celltrion Company Details
11.1.2 Company Business Overview
11.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Celltrion Biosimilar Monoclonal Antibodies Products Offered
11.1.5 Celltrion Recent Development
11.2 Pfizer (Hospira)
11.2.1 Pfizer (Hospira) Company Details
11.2.2 Company Business Overview
11.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Products Offered
11.2.5 Pfizer (Hospira) Recent Development
11.3 3SBIO
11.3.1 3SBIO Company Details
11.3.2 Company Business Overview
11.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.3.4 3SBIO Biosimilar Monoclonal Antibodies Products Offered
11.3.5 3SBIO Recent Development
11.4 Novartis (Sandoz)
11.4.1 Novartis (Sandoz) Company Details
11.4.2 Company Business Overview
11.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Products Offered
11.4.5 Novartis (Sandoz) Recent Development
11.5 Dr Reddy's
11.5.1 Dr Reddy's Company Details
11.5.2 Company Business Overview
11.5.3 Dr Reddy's Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Dr Reddy's Biosimilar Monoclonal Antibodies Products Offered
11.5.5 Dr Reddy's Recent Development
11.6 Celgen Biopharma
11.6.1 Celgen Biopharma Company Details
11.6.2 Company Business Overview
11.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Products Offered
11.6.5 Celgen Biopharma Recent Development
11.7 Cadila Healthcare
11.7.1 Cadila Healthcare Company Details
11.7.2 Company Business Overview
11.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Products Offered
11.7.5 Cadila Healthcare Recent Development
11.8 Hisun Pharma
11.8.1 Hisun Pharma Company Details
11.8.2 Company Business Overview
11.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Products Offered
11.8.5 Hisun Pharma Recent Development
11.9 Torrent Pharmaceuticals
11.9.1 Torrent Pharmaceuticals Company Details
11.9.2 Company Business Overview
11.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Products Offered
11.9.5 Torrent Pharmaceuticals Recent Development

12 Future Forecast
12.1 Biosimilar Monoclonal Antibodies Market Forecast by Regions
12.1.1 Global Biosimilar Monoclonal Antibodies Sales Forecast by Regions 2019-2025
12.1.2 Global Biosimilar Monoclonal Antibodies Revenue Forecast by Regions 2019-2025
12.2 Biosimilar Monoclonal Antibodies Market Forecast by Product
12.2.1 Global Biosimilar Monoclonal Antibodies Sales Forecast by Product 2019-2025
12.2.2 Global Biosimilar Monoclonal Antibodies Revenue Forecast by Product 2019-2025
12.3 Biosimilar Monoclonal Antibodies Market Forecast by End User
12.4 North America Biosimilar Monoclonal Antibodies Forecast
12.5 Europe Biosimilar Monoclonal Antibodies Forecast
12.6 Asia Pacific Biosimilar Monoclonal Antibodies Forecast
12.7 Central & South America Biosimilar Monoclonal Antibodies Forecast
12.8 Middle East and Africa Biosimilar Monoclonal Antibodies Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Biosimilar Monoclonal Antibodies Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

Quick Buy This Premium Report From Here: http://www.amecoresearch.com/buy/11735

About Ameco Research
Ameco Research is the one spot destination for all your research needs. Ameco Research holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.

Contact:
Email:sales@amecoresearch.com | + 1 407 915 4157